TP Therapeutics raises $45 mln
TP Therapeutics Inc has raised $45 million in a Series C financing round co-led by Lilly Asia Ventures (LAV), OrbiMed Advisors LLC and S.R. One Ltd. The round was joined by existing investors Cormorant Asset Management and SV Tech Ventures. TP Therapeutics, of San Diego, is a clinical-stage biopharmaceutical company focused on addressing oncology drug resistance.
23 May 2017•3 mins read
